免疫激活的多模式标志物预测了帕金森病的认知结果
K M Scott1, L R B Spindler2, A R D Peattie2
1Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 0PY, UK; Department of Neurology, Box 165, Cambridge University Hospitals NHS Trust, Hills Road, Cambridge CB2 0QQ, UK.
Brain, behavior, and immunity
|May 27, 2025
概括
帕金森病 (PD) 中的炎症标志物预测认知能力下降. 增加激活的CD4T细胞,B细胞向中枢神经系统迁移,以及黑质体炎症是关键指标.
科学领域:
- 神经免疫学 神经免疫学
- 神经退行性疾病 神经退行性疾病
- 生物标志物发现发现
背景情况:
- 帕金森病 (PD) 涉及中枢神经系统 (CNS) 和外周炎症,可能增加痴呆风险.
- 识别PD认知衰退的免疫生物标志物的长度研究很少.
研究的目的:
- 确定外周和中枢神经系统免疫生物标志物,预测早期帕金森病的认知衰退.
- 在3年的时间内调查神经炎症和认知结果之间的关系.
主要方法:
- 从新诊断的PD患者和对照组收集的外周血液单核细胞和脑脊液 (CSF) 免疫细胞.
- 通过流细胞计进行了免疫类型定型,计算了CSF:血液比率,并进行了11C-PK11195PET MRI扫描以评估神经炎症.
- 在临床上对参与者进行了3年的跟踪,以评估认知结果.
主要成果:
- 确定了22个免疫变量,区分认知障碍PD患者 (PD-CI) 与无障碍PD患者 (PD-NCI) 和对照.
- 在PD-CI中观察到血液中激活的CD4 T细胞的比例较高,以及脑流体:记忆B细胞的血液比率增加.
- 黑色体炎症 (11C-PK11195 BPND) 和脑脊液:血液内存B细胞比率在基线预测了3年的认知衰退.
结论:
- 高度激活的CD4细胞,B细胞向中枢神经系统迁移,黑体质炎症预测PD的认知衰退.
- 这些标记物可以作为PD免疫/炎症分层的生物标记物.
- 这些发现支持针对微质炎症或早期PD的淋巴细胞招募的治疗策略.
更多相关视频
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
7.8K
08:09Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
7.5K
相关概念视频
Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
Parkinson's Disease: Overview
498
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
498
